Alnylam Grants Calando a License to Develop and Commercialize an RNAi Therapeutic Product
Target-Specific License for RNAi Intellectual Property Granted under Alnylam's InterfeRx(TM) Program
23-Aug-2006 -
Alnylam Pharmaceuticals, Inc. has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx(TM) license to discover, develop, and commercialize an RNAi therapeutic utilizing a synthetic siRNA, together exclusively with Calando's proprietary ...
Alnylam
milestone payments